Skip to content
OpenCapital
Get started

Niagen Bioscience, Inc. Common Stock NAGE Q4 2025 Annual earnings

Reported March 4, 2026 · After market close

Revenue$33.8MBeat by $2.1MDiluted EPS$0.03Beat by $0.01
Revenue estimate$31.7M
EPS estimate$0.02

Next report

Aug 5, 2026 (in a month)
Revenue estimate$31.7M
EPS estimate$0.01

Financials

Q4 2025

Income statement

See full
Revenue$33.8M+16.2%
Gross profit$21.7M+19.3%
Operating income$4.1M-42.5%
Net income$4.1M-42.4%
EPS (diluted)$0.05-44.4%

Balance sheet

See full
Cash & equivalents$64.8M+45.1%
Total debt$2.8M+7.2%
Total equity$76.5M+66.0%
Total assets$106.4M+55.8%

Cash flow

See full
Operating cash flow$679.0K-92.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$507.57M—
Enterprise value$445.58M—
P/E29.2×—
P/S3.9×—

Profitability

See full
Gross margin64.3%+2.4pp
Operating margin12.6%+4.8pp
Net margin13.4%+4.8pp

Returns & leverage

See full
Return on equity28.3%+5.4pp
Debt / equity0×0.0×
Current ratio4.9×+1.3×

Versus estimates

Revenue

Q1 2026$31.5MBeat by $444.0K
Q4 2025$33.8MBeat by $2.1M
Q3 2025$34.0MBeat by $2.9MQ2 2025$31.1MBeat by $354.8KQ1 2025$30.5MBeat by $3.4MQ4 2024$29.1MBeat by $2.4M

Diluted EPS

Q1 2026$0.07Beat by $0.01
Q4 2025$0.03Beat by $0.01
Q3 2025$0.05Beat by $0.04Q2 2025$0.04Beat by $0.02Q1 2025$0.04Beat by $0.02Q4 2024$0.03Beat by $0.01

Ask the moment Niagen Bioscience, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Niagen Bioscience, Inc. Common Stock report Q4 2025 earnings?
Niagen Bioscience, Inc. Common Stock (NAGE) reported Q4 2025 earnings on March 4, 2026 after market close.
What were Niagen Bioscience, Inc. Common Stock's Q4 2025 revenue and EPS?
Niagen Bioscience, Inc. Common Stock reported revenue of $33.8M and diluted EPS of $0.03 for Q4 2025.
Did Niagen Bioscience, Inc. Common Stock beat estimates in Q4 2025?
Revenue beat the consensus estimate of $31.7M by $2.1M. EPS beat the consensus estimate of $0.02 by $0.01.
How did Niagen Bioscience, Inc. Common Stock's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 16.2% from $29.1M a year earlier and diluted EPS grew 0.0% from $0.03.
Where can I find Niagen Bioscience, Inc. Common Stock's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001386570-26-000014) and the 10-K periodic report (0001386570-26-000013) directly on SEC EDGAR. The filing index links above go to sec.gov.